Breast Cancer

New chemotherapy agent highlighted in oncology studies

Published in Women's Health Weekly, July 3rd, 2003

Taxotere (docetaxel) Injection Concentrate, an active chemotherapy agent, showed positive results in various treatment regimens in early and advanced breast cancer according to numerous phase II and III clinical studies presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Among the studies involving Taxotere at this year's ASCO, several focused on the use of Taxotere to treat women with early stage breast cancer before (neoadjuvant) or after (adjuvant) surgery, as well as women with advanced disease.

Three-year results of a prospective, randomized trial of adjuvant therapy among patients with stage I-III operable,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry